New Delhi: In a report submitted to the Ministry of Health and Family Welfare by the National AEFI (Adverse Event after Immunization) Committee, it is said that there are very few cases of bleeding and clotting in India after Covid vaccination and this is the situation in the country.
Corresponds to the expected number of encounters. On March 11, 2021, alerts have been issued in some countries, specifically with the Astra Zeneca-Oxford vaccine [Covishield in India], following the “incidence of bleeding and clotting” after vaccination. In view of global concerns, it was decided to conduct an in-depth analysis of adverse events (AEs) in India immediately.
The National AEFI Committee has noted that as of April 3, 2021, 7,54,35,381 doses of vaccine (covishield- 6,86,50,819; covaxine-67,84,562) have been applied. These included 6,59,44,106 first doses and 94,91,275 second doses. Since the launch of the Covid-19 vaccination campaign, more than 23,000 adverse events (AEs) were reported through the Co-Win platform in 684 out of 753 districts in the country. Of these, only 700 cases (@ 9.3 cases / 10 lakh vaccine dose) were reported to be of a serious and complex nature.
The AEFI committee has completed an in-depth review of 498 cases with serious and complex events, of which 26 cases have been reported as possible thromboembolic events (clotting in the blood vessel, with a reported rate of 0.61 cases / 1 million dose after covicilloid vaccination, which May be loose, the distance through the bloodstream to the blood vessel).
Not a single case of possible thromboembolic has been reported after applying covaxine vaccine.
AEFI data in India have shown that there is a very low, but definitely increased risk of thromboembolic events. The rate of reporting such complaints (reporting rate) in India is around 0.61 / 10 lakh doses, which is much lower than the 4 cases / 10 lakh doses reported by the UK Medical and Health Regulatory Authority (MHRA). Germany has recorded 10 such incidents per 1 million doses.
It is extremely important to know that the incidence of thromboembolic also continues to occur in the general population, as circumstances and scientific studies suggest that this risk is approximately 70 percent lower in individuals of South and Southeast Asian descent than individuals of European descent. .
The Ministry of Health and Family Welfare is issuing separate advisories to health care workers and vaccinated beneficiaries, to allow people with suspected thromboembolic symptoms to occur within 20 days after applying any Kovid-19 vaccine (especially Covishield). Be aware of and be encouraged to report any such incident to the health center where the vaccine was vaccinated:
Pain in the limbs / pain on the limbs or swelling of the limbs (arms or calves);
Multiple, needle-tip red spots or blue-black spots in the skin outside the injected area;
Constant abdominal pain with or without relapse;
Seizures, with or without relapse, having no prior problems of relapse;
Fast and frequent headaches with or without relapse (despite no prior problem of migraine or chronic headache);
• Weakness / paralysis in any particular part of the body or organs (including the face) or any part of the body;
Constant reversal for no apparent reason;
Blurred look or pain in the eyes or a couple of pictures;
A change in mental state or confusion or consciousness at the level of depression
Any other symptom or health condition that is of concern to the person or family applying the vaccine
Covishield, the Covid-19 vaccine, continues to identify definitively positive benefit risks, with a tremendous ability to consistently prevent infections and reduce deaths due to Covid-19 throughout the world and India. In India, more than 13.4 million doses of the Covishield vaccine have been given as of April 27, 2021. The Ministry of Health and Family Welfare is constantly monitoring the safety of all Covid-19 vaccines and is also encouraging the reporting of suspected adverse events.